Ruddon Molecular Biology of Cancer: Translation to the Clinic

1. Auflage 2010
ISBN: 978-0-12-385072-0
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, Band Volume 95, 400 Seiten

Reihe: Progress in Molecular Biology and Translational Science

Advances in molecular biology over the last several decades are being steadily applied to our understanding of the molecular biology of cancer, and these advances in knowledge are being translated into the clinical practice of oncology. This volume explores some of the most exciting recent advances in basic research on the molecular biology of cancer and how this knowledge is leading to advances in the diagnosis, treatment, and prevention of cancer. - This series provides a forum for discussion of new discoveries, approaches, and ideas - Contributions from leading scholars and industry experts - Reference guide for researchers involved in molecular biology and related fields

Autoren/Hrsg.

Ruddon, Raymond

Inhaltsverzeichnis

1;Front Cover;1
2;Progress In Molecular Biology and Translational Science Molecular Biology of Cancer:Translation to the Clinic;4
3;Copyright;5
4;Contents;6
5;Contributors;10
6;Preface;12
7;Chapter 1: Introduction to the Molecular Biology of Cancer;14
7.1;References;20
8;Chapter 2: Molecular Biology and Anticancer Drug Discovery;22
8.1;I. Introduction;22
8.2;II. Phenotypic Targets;25
8.3;III. Molecular Targets;29
8.4;IV. Other Contemporary Issues in Anticancer Drug Discovery;39
8.5;V. Conclusions;40
8.6;References;40
9;Chapter 3: Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic;44
9.1;I. Biology of CCL2;45
9.2;II. CCL2 in Prostate Cancer;50
9.3;III. CCL2 Development as a Therapeutic Target;54
9.4;IV. Conflicting Reports on the Roles of CCL2 in Cancer;56
9.5;V. Conclusions;56
9.6;Acknowledgments;57
9.7;References;58
10;Chapter 4: Chromosomal Aberrations in Solid Tumors;68
10.1;I. Introduction;69
10.2;II. Historical Background: Discovery of Chromosome Aberrations in Cancer;70
10.3;III. Discovery of Gene Fusions in Cancer;71
10.4;IV. New Approaches for Gene Fusion Identification;74
10.5;V. Methods for the Characterization of Chromosome Aberrations in Solid Tumors;83
10.6;VI. Next-Generation Sequencing Technology;92
10.7;VII. Structural Classification of Gene Fusions;95
10.8;VIII. Functional Classification of Gene Fusions;96
10.9;IX. Mechanism of the Formation of Gene Fusions in Cancer;97
10.10;References;99
11;Chapter 5: Circulating Tumor Cells;108
11.1;I. Introduction;109
11.2;II. What Are the Technological Issues?;109
11.3;III. What Are the Clinical Utilities of CTCs Detection and Enumeration?;113
11.4;IV. CTC Characterization;119
11.5;V. Summary;120
11.6;References;121
12;Chapter 6: Stem Cells in Normal Development and Cancer;126
12.1;I. Introduction of Cancer Stem Cells and the Cancer Stem Cell Hypothesis;127
12.2;II. Comparison of Normal Stem Cells with Cancer Stem Cells;128
12.3;III. Definition of Cancer Stem Cells and Identification of Cancer Stem Cell Markers;130
12.4;IV. Identification of Cancer Stem Cells;136
12.5;V. Activation of Signaling Pathways and Targeted Therapies for Cancer Stem Cells;142
12.6;VI. Therapeutic Implications for Targeting Cancer Stem Cells;156
12.7;VII. Conclusions;157
12.8;References;158
13;Chapter 7: Bioinformatics and Systems Biology of Cancers;172
13.1;I. Introduction;173
13.2;II. The Cancer Biomedical Informatics Grid (caBIG);175
13.3;III. TCGA: The Cancer Genome Anatomy Project;178
13.4;IV. Alternative Splicing: Discovery of a New Class of Protein Cancer Biomarker Candidates;185
13.5;V. Concepts Tools for Systems Biology Analysis;194
13.6;VI. Determining the Activity of All 21,000 Protein-Coding Genes in the Human Genome;196
13.7;VII. Bioinformatics and Systems Biology of Metastasis: The Case of Lung Cancers;197
13.8;VIII. Special Resources for Pharmacogenomics of Cancer Therapies;198
13.9;IX. Conclusion;200
13.10;Acknowledgment;201
13.11;References;201
14;Chapter 8: Progress in Cancer Nanotechnology;206
14.1;I. Introduction and Historical Perspective;207
14.2;II. Targeted Therapy;208
14.3;III. Computer Simulations as an Approach to Develop Nanotechnology in Cancer;209
14.4;IV. Nanomolecular Carriers for Drugs and Imaging Agents;213
14.5;V. Nanotechnology in Cancer-Targeted Delivery of Therapeutic Agents;220
14.6;VI. Targeted Imaging;229
14.7;VII. Apoptosis Sensors;232
14.8;VIII. Future Direction in Research and Technology;240
14.9;References;241
15;Chapter 9: Applications of Molecular Imaging;250
15.1;I. Optical Imaging;251
15.2;II. Magnetic Resonance Imaging;270
15.3;III. Nuclear Imaging;284
15.4;Acknowledgments;299
15.5;References;299
16;Chapter 10: Cancer Epigenetics;312
16.1;I. Introduction;312
16.2;II. First, a Little History;313
16.3;III. Epigenetic Patterns in Normal Cells;315
16.4;IV. Epigenetic Patterns in Cancer;339
16.5;V. Epigenetic Therapies for Cancer;350
16.6;VI. Prospects for the Future of Cancer Epigenetics;355
16.7;References;357
17;Chapter 11: Molecular Targets and Clinical Cancer Risk Reductive Interventions;364
17.1;I. Defining Cancer Risk Reductive Intervention (Chemoprevention);364
17.2;II. Cellular Transformational Molecular Events as Targets for CRRIs;365
17.3;III. Inherited Genetic Mutations (Cancer Susceptibility Syndromes);365
17.4;IV. Special Features of CRRI Development;368
17.5;V. Molecular Intermediates as Biomarkers for Cancer Risk Reductive Efficacy;369
17.6;VI. Future Approaches to Molecular Biomarker Applications to CRRI;371
17.7;VII. Standards for Biomarkers as Endpoints for Cancer Risk Reductive Efficacy;371
17.8;VIII. Examples of CRRIs and Their Molecular Targets;371
17.9;IX. Nutritional Products;376
17.10;X. Multiagent CRRIs;377
17.11;XI. Molecular Viral Targets for Cancer Risk Reduction;377
17.12;References;379
18;Index;390